A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma
Plain-language summary
This trial is testing allogeneic stem cell transplant (from a donor) for patients with various types of peripheral T-cell lymphoma (PTCL) who have responded to prior therapy and may receive maintenance treatment. This is a Phase 2/3 trial that tests how well the treatment works and may compare it to standard care. This trial does not currently have sites in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years to 70 Years years
- Must have responded to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Cidabenamine, Azacitidine (DRUG): In the study, Cidabenamine combined with Azacitidine are used as maintenance therapy following allogeneic peripheral blood hematopoietic stem cell transplantation in patients with high-risk peripheral T-cell lymphoma.
Cidabenamine, Azacitidine
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details